Chemotherapy and complications in gynecologic cancer

Ww, ten Bokkel Huinink

doi:10.1097/00001622-199110000-00018

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resulting nausea and vomiting are the major complaints among cisplatin-treated patients [13]. Use of 5-hydroxytryptamine 3 inhibitors (e.g., granisetron, ondansetron, and tropisetron) can reduce the incidence and severity of these effects [14].…”

Section: Platinum Agentsmentioning

confidence: 99%

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

Dunton

2002

The Oncologist

View full text Add to dashboard Cite

Recognition of recurrent ovarian cancer as a disease with significant secondary responses and remissions has led to an increase in the need for oncologists to plan for the long-term therapy of patients. However, many of the currently available front-line and salvage agents used in advanced ovarian cancer are associated with cumulative and/or irreversible toxicities that pose challenges in longterm planning. The irreversible effects associated with some of these therapies may render patients less tolerant to subsequent treatments and lead to a cycle of diminishing treatment options with each remission and disease relapse. Additionally, the potential for patients to experience cumulative toxicity must be carefully weighed against the goals of prolonging the disease-free interval and improving patient quality of life. A number of agents are available in the treatment armamentarium (platinum, paclitaxel, gemcitabine, etoposide, liposomal doxorubicin, and topotecan), many, but not all of which are associated with cumulative toxicity. For instance, cumulative neurotoxicity associated with cisplatin as first-line therapy may diminish the option for retreatment with platinum at first relapse. In contrast, the main toxicity associated with topotecan is noncumulative, manageable myelosuppression. In this review, the major toxicities associated with the predominant chemotherapy agents used in advanced ovarian cancer are discussed along with selected management approaches in the context of long-term treatment planning and sequencing.

show abstract

Section: Platinum Agentsmentioning

confidence: 99%

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

Dunton

2002

The Oncologist

View full text Add to dashboard Cite

show abstract

“…The maximum dose was limited by peritoneal irritation, but a range of 10 – 55 mg/m 2 with a median number of five instillations was achieved. There were three complete remissions observed at dose levels of 20 – 25 mg/m 2 39 …”

Section: Ovarian Carcinomamentioning

confidence: 97%

An Overview of Mitozantrone

Birchall

Bailey

Blackledge

1991

Int J Clinical Practice

View full text Add to dashboard Cite

INTRODUCTION Mitozantrone is a member of the anthraquinone group of chemicals. Anthraquinones were used as blue dyes in the fabric industry in the early 20th century, and subsequently in ballpoint pen ink as ametantrone.1 Since the discovery of doxorubicin in 1968 searches have continued for anthracycline‐related compounds with improved efficacy and/or a different spectrum of activity with less toxicity.

show abstract

The role of glutathione in combination with cisplatin in the treatment of ovarian cancer

Tedeschi¹

1991

Cancer Treatment Reviews

View full text Add to dashboard Cite

Chemotherapy and complications in gynecologic cancer

Cited by 7 publications

References 0 publications

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

An Overview of Mitozantrone

The role of glutathione in combination with cisplatin in the treatment of ovarian cancer

Contact Info

Product

Resources

About